Subcutaneous Amivantamab
PALOMA: Phase Ib Trial of Subcutaneous Amivantamab Given Every 4 Wk in Patients With Advanced Solid Tumors

Released: May 02, 2024

Expiration: May 01, 2025

Activity

Progress
1
Course Completed